Introduction
Previous studies have reported increased risk of second cancer in both esophageal squamous cell cancer (ESCC) and esophageal adenocarcinoma (EAC) survivors during follow-up, and the risk varied across cancer types.
Aims & Methods
Aimed to examine the risk and influential factors of second cancer in ESCC and EAC patients, this population-based study included 7,297 ESCC patients and 11,812 EAC patients who were in 1992-2019 from the Surveillance, Epidemiology, and End Results (SEER) program in the United States. These patients were followed up until diagnosis of second cancer, death, or end of the study (December 31, 2019). We calculated standard incidence ratio (SIR) and 95% confidence interval (CI) of second cancer and performed competing-risk regression to estimate the subdistribution hazard ratios (sHR) comparing categories of patients’ characteristics.
Results
After a total of 49509.38 person-years of follow-up, 431 (5.9%) ESCC patients and 636 (5.9%) EAC patients developed a second cancer. An overall increased risk of second cancer was observed in both ESCC patients (SIR=1.66, 95% CI 1.51-1. 83) and EAC patients (SIR=1.11, 95% CI 1.02-1.20). ESCC patients were at increased risk of second malignancy in oral cavity and pharynx (SIR=12.57, 95% CI 9.87-15.79), stomach (SIR=3.03, 95% CI 1.77-4.85), nose and larynx (SIR=4.79, 95% CI 2.47-8.37), and lung and bronchus (SIR=2.44, 95% CI 1.96-2.99), but decreased risk of prostate cancer (SIR=0.73, 95% CI 0.52-0.99). EAC patients had increased risk of second malignancies in stomach (SIR=4.41, 95% CI 3.23-5.89), lung and bronchus (SIR=1.26, 95% CI 1.02-1.54), and kidney (SIR=1.57, 95% CI 1.05-2.25). The risk of second cancer was higher in female ESCC patients than in males (sHR=1.34, 95% CI 1.11-1.63) and decreased with more advanced tumor stage for in both ESCC patients (sHR=0.62, 95% CI 0.50-0.76 for localized stage; sHR=0.27, 95% CI 0.20-0.36 for distant stage) and EAC patients (sHR=0.47, 95% CI 0.40-0.56 for localized stage; sHR=0.10, 95% CI 0.07-0.13 for distant stage).
Conclusion
Both ESCC and EAC patients are at considerable risk of certain types of second cancer.
References
1.Tanjak, P., et al., Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study. BMC Cancer, 2021. 21(1): p. 1045.
2.Allemani, C., et al., Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018. 391(10125): p. 1023-1075.
3.Lee, G.D., et al., Esophageal Cancer Associated with Multiple Primary Cancers: Surgical Approaches and Long-term Survival. Ann Surg Oncol, 2013. 20(13): p. 4260-6.
4.Lee, J.S., et al., Synchronous second primary cancers in patients with squamous esophageal cancer: clinical features and survival outcome. Korean J Intern Med, 2016. 31(2): p. 253-9.
5.Baba, Y., et al., Clinical and Prognostic Features of Patients With Esophageal Cancer and Multiple Primary Cancers: A Retrospective Single-institution Study. Ann Surg, 2018. 267(3): p. 478-483.
6.Copur, M.S. and S. Manapuram, Multiple Primary Tumors Over a Lifetime. Oncology (Williston Park), 2019. 33(7).
7.Boffetta, P., et al., The burden of cancer attributable to alcohol drinking. Int J Cancer, 2006. 119(4): p. 884-7.
8.Andersen, P.K., et al., Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol, 2012. 41(3): p. 861-70.
